1-(4-Chlorophenyl)-3-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Chlorophenyl)-3-[3-[8-(methylamino)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea
• 化学式: C₂₀H₁₇ClN₆O
• 分子量: 392.8
• InChiKey: DUQNCKBDHGRGKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  83.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
  申请人：——

  公开号：US20030212073A1

  公开（公告）日：2003-11-13

  A novel composition comprises a compound of Formula 1 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.

  一种新型组合物包括公式11的化合物，其药学上可接受的盐、水合物、溶剂物、晶体形态、对映体、前药或其混合物。该组合物在治疗激酶相关疾病方面具有特殊的用途。
• Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
  申请人：Currie S. Kevin

  公开号：US20050288295A1

  公开（公告）日：2005-12-29

  At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, and prodrugs thereof. Methods of treating or preventing disorders in which aberrant kinase activity is implicated, pharmaceutically compositions, and methods for detecting the presence kinases in cells or biological preparations and for identifying kinases of therapeutic interest.

  至少选择来自化合物1的化学实体和药学上可接受的药学上可接受的盐、水合物、溶剂合物、晶体形式、对映体和前药。用于治疗或预防与异常激酶活性有关的疾病的方法，药物组合物，以及检测细胞或生物制剂中激酶的存在和鉴定治疗性激酶的方法。
• IMIDAZO(1,2-A)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：Cellular Genomics Inc.

  公开号：EP1509526A2

  公开（公告）日：2005-03-02
• US6919340B2
  申请人：——

  公开号：US6919340B2

  公开（公告）日：2005-07-19
• [EN] IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF<br/>[FR] IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES, LEUR PROCEDE DE PRODUCTION ET LEUR UTILISATION
  申请人：CELLULAR GENOMICS INC

  公开号：WO2003089434A2

  公开（公告）日：2003-10-30

  A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.